These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22614936)

  • 21. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.
    Fiellin DA; Barry DT; Sullivan LE; Cutter CJ; Moore BA; O'Connor PG; Schottenfeld RS
    Am J Med; 2013 Jan; 126(1):74.e11-7. PubMed ID: 23260506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of heroin dependence with buprenorphine in primary care.
    Fiellin DA; Pantalon MV; Pakes JP; O'Connor PG; Chawarski M; Schottenfeld RS
    Am J Drug Alcohol Abuse; 2002; 28(2):231-41. PubMed ID: 12014814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of adding behavioral treatment to opioid detoxification with buprenorphine.
    Bickel WK; Amass L; Higgins ST; Badger GJ; Esch RA
    J Consult Clin Psychol; 1997 Oct; 65(5):803-10. PubMed ID: 9337499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment.
    Barry DT; Moore BA; Pantalon MV; Chawarski MC; Sullivan LE; O'Connor PG; Schottenfeld RS; Fiellin DA
    J Gen Intern Med; 2007 Feb; 22(2):242-5. PubMed ID: 17356993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
    Sanders NC; Mancino MJ; Gentry WB; Guise JB; Bickel WK; Thostenson J; Oliveto AH
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):294-302. PubMed ID: 23855333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting.
    Godersky ME; Klein JW; Merrill JO; Blalock KL; Saxon AJ; Samet JH; Tsui JI
    J Addict Med; 2020; 14(4):319-325. PubMed ID: 31972762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
    Tsui JI; Leroux BG; Radick AC; Schramm ZA; Blalock K; Labelle C; Heerema M; Klein JW; Merrill JO; Saxon AJ; Samet JH; Kim TW
    Drug Alcohol Depend; 2021 Oct; 227():108917. PubMed ID: 34399136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing.
    McHugh RK; Fitzmaurice GM; Votaw VR; Geyer RB; Ragnini K; Greenfield SF; Weiss RD
    J Subst Use Addict Treat; 2024 May; 160():209296. PubMed ID: 38272120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
    Sullivan M; Bisaga A; Pavlicova M; Choi CJ; Mishlen K; Carpenter KM; Levin FR; Dakwar E; Mariani JJ; Nunes EV
    Am J Psychiatry; 2017 May; 174(5):459-467. PubMed ID: 28068780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
    Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
    J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients.
    Bickel WK; Amass L; Crean JP; Badger GJ
    Psychopharmacology (Berl); 1999 Sep; 146(2):111-8. PubMed ID: 10525745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
    Krook AL; Stokka D; Heger B; Nygaard E
    Eur Addict Res; 2007; 13(4):216-21. PubMed ID: 17851243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
    Kowalczyk WJ; Moran LM; Bertz JW; Phillips KA; Ghitza UE; Vahabzadeh M; Lin JL; Epstein DH; Preston KL
    Am J Drug Alcohol Abuse; 2018; 44(5):502-511. PubMed ID: 29634425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.